A composition for reducing fat and uric acid, a preparation method, application and product thereof

Abstract

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a composition for reducing fat and uric acid, a preparation method, application and product thereof. The composition is composed of the following raw materials: Ilex hainanensis Merr., Crataegus pseudoheterophylla, Folium Nelumbinis, Pueraria lobata, Imperata cylindrica and Litchi chinensis Sonn. After the raw materials are crushed and sliced, the composition is prepared by auxiliary extraction with sophorolipid, stepwise enzymatic hydrolysis with aminopeptidase, cellulase and acid protease, and then filtration, concentration and drying. The composition can be applied to the preparation of health care products for helping to control fat in the body and medicines for reducing body fat or uric acid. Compared with the existing products, the composition has an advanced preparation process, can effectively improve the dissolution rate of effective components, has a clear mechanism, and is natural and safe, has a significant effect on reducing fat and uric acid, and has important application value and broad market prospects.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a composition for reducing fat and lowering uric acid, its preparation method, application, and product. Background Technology

[0002] Obesity is not only an external manifestation of excessive fat accumulation in the body, but also a key risk factor for metabolic syndromes such as cardiovascular disease, diabetes, and fatty liver. Meanwhile, hyperuricemia, a metabolic disease caused by purine metabolism disorders or impaired uric acid excretion, can easily develop into gout if left uncontrolled for a long time, leading to joint pain, deformities, and even kidney damage. Studies show that obesity and hyperuricemia are closely related in their pathogenesis, often influencing each other and forming a vicious cycle that further exacerbates disease progression.

[0003] Currently, there are numerous products on the market targeting fat loss and uric acid reduction. Western medicine fat loss products, such as orlistat, can reduce fat absorption by inhibiting gastrointestinal lipase, but they are often accompanied by side effects such as gastrointestinal discomfort and malabsorption of fat-soluble vitamins. Uric acid-lowering drugs, such as allopurinol and febuxostat, mainly reduce uric acid production by inhibiting xanthine oxidase, or, like benzbromarone, by promoting uric acid excretion. However, these drugs have adverse reactions such as allergic reactions, liver damage, and urate crystal deposition, and long-term use can easily lead to drug resistance, limiting their clinical application.

[0004] In the field of traditional Chinese medicine, research on the effects of Chinese herbal compositions on reducing fat and lowering uric acid has yielded certain results. Patent CN102771861B describes a functional beverage containing ingredients such as kudzu root, mulberry leaf, sophora flower, hawthorn, coix seed, fresh imperata root, chrysanthemum, yam, prunella vulgaris, mesona chinensis, mint, wolfberry, lotus leaf, and cassia seed, thereby achieving the effects of preventing high blood pressure, high cholesterol, and high blood sugar, preventing obesity, and preventing internal heat. Patent CN110236041A provides a plant-based beverage containing the following ingredients: coix seed, red bean, fresh imperata root, kudzu root, dried bitter melon, hemp seed, jujube seed, apricot kernel, rice vinegar, green tea leaves, lotus leaf, purslane, wolfberry, hawthorn, and honey, which has excellent therapeutic effects on high blood lipids, high blood viscosity, high uric acid, and high blood sugar.

[0005] However, existing traditional Chinese medicine (TCM) compositions suffer from problems such as complex composition and low dissolution rate of active ingredients. Some TCM compound prescriptions are simply formulated without scientific basis or optimized screening. Furthermore, traditional methods such as decoction are insufficient to fully extract active ingredients during preparation, leading to unstable efficacy and failing to meet modern clinical and market demands. Therefore, developing a safe and effective composition for weight loss and uric acid reduction is of great significance. Summary of the Invention

[0006] To address the above shortcomings, this invention provides a composition for reducing fat and lowering uric acid, its preparation method, application, and product.

[0007] The technical solution of this invention is as follows:

[0008] On the one hand, the present invention provides a composition for reducing fat and lowering uric acid, the composition being composed of the following raw materials: Buzha leaf, Crataegus pinnatifida, lotus leaf, Pueraria lobata root, Imperata cylindrica root, and litchi seed;

[0009] The preparation method of the composition is as follows:

[0010] S1. After crushing and sieving the leaves of Buzha and lotus, mix them to obtain medicinal powder 1;

[0011] S2. Remove the pits from the hawthorn, crush it into powder and sieve it. Crush the lychee seeds into granules and mix them together to obtain medicinal powder 2.

[0012] S3. Mix the sliced ​​Pueraria lobata and Imperata cylindrica, add distilled water, stir well, add sophoryl ester, soak, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0013] S4. Combine the medicinal powder 1 and the dregs 1, add buffer solution, add aminopeptidase and cellulase, enzymatically hydrolyze, inactivate enzymes, filter, and obtain enzymatic hydrolysate 1 and dregs 2.

[0014] S5. Combine the medicinal powder 2 and the dregs 2, add distilled water, adjust the pH, add acidic protease, hydrolyze, inactivate the enzyme, filter, and obtain enzymatic hydrolysate 2.

[0015] S6. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0016] S7. Filter the enzymatic extract, concentrate and dry to obtain the composition.

[0017] Specifically, the sieving mentioned in step S1 is: passing through a sieve of at least 40 mesh.

[0018] Preferably, the sieving in step S1 is: sieving through a 40-mesh sieve, a 50-mesh sieve, a 60-mesh sieve, a 70-mesh sieve, an 80-mesh sieve, a 100-mesh sieve, a 120-mesh sieve, a 140-mesh sieve, a 170-mesh sieve, or a 200-mesh sieve.

[0019] More preferably, the sieving in step S1 is: sieving through a 40-mesh sieve.

[0020] Specifically, the sieving mentioned in step S2 is: passing through a sieve of at least 50 mesh.

[0021] Preferably, the sieving in step S2 is: 50 mesh sieve, 60 mesh sieve, 70 mesh sieve, 80 mesh sieve, 100 mesh sieve, 120 mesh sieve, 140 mesh sieve, 170 mesh sieve or 200 mesh sieve.

[0022] Preferably, the sieving in step S2 is: sieving through a 50-mesh sieve.

[0023] Specifically, the amount of sophoryl ester added in step S3 is 0.5%-1.0% w / w of the mass of distilled water mentioned in step S3.

[0024] Preferably, the amount of sophoryl ester added in step S3 is 0.50%-0.55%w / w, 0.55%-0.60%w / w, 0.60%-0.65%w / w, 0.65%-0.70%w / w, 0.70%-0.75%w / w, 0.75%-0.80%w / w, 0.80%-0.85%w / w, 0.85%-0.90%w / w, 0.90%-0.95%w / w, or 0.95%-1.00%w / w of the mass of distilled water in step S3.

[0025] More preferably, the amount of sophoroid ester added in step S3 is 0.50% w / w, 0.75% w / w, or 1.00% w / w of the mass of distilled water in step S3.

[0026] More preferably, the amount of sophoroside ester added in step S3 is 0.50% w / w of the mass of distilled water in step S3.

[0027] Specifically, the distilled water mentioned in step S3 is added at a material-to-liquid ratio of 1g:10-15mL.

[0028] Preferably, the distilled water in step S3 is added at a material-to-liquid ratio of 1g:10-11mL, 1g:11-12mL, 1g:12-13mL, 1g:13-14mL or 1g:14-15mL.

[0029] More preferably, the distilled water in step S3 is added at a material-to-liquid ratio of 1g:10mL or 1g:15mL.

[0030] More preferably, the distilled water in step S3 is prepared at a material-to-liquid ratio of 1g:10mL.

[0031] Specifically, the soaking described in step S1 is for 60-120 minutes.

[0032] Preferably, the soaking in step S1 is for 60-70 min, 70-80 min, 80-90 min, 90-100 min, 100-110 min, or 110-120 min.

[0033] More preferably, the soaking in step S3 is for 60 minutes.

[0034] Specifically, the extraction temperature described in step S3 is 40-60℃.

[0035] Preferably, the extraction temperature in step S3 is 40-45℃, 45-50℃, 50-55℃ or 55-60℃.

[0036] More preferably, the extraction temperature in step S3 is 50°C.

[0037] Specifically, the extraction time described in step S3 is 30-50 minutes.

[0038] Preferably, the extraction time in step S3 is 30-40 min or 40-50 min.

[0039] More preferably, the extraction time in step S3 is 40 minutes.

[0040] Specifically, the amount of aminopeptidase added in step S4 is 1.0%-1.5% w / w of the mass of the buffer solution mentioned in step S4.

[0041] Preferably, the amount of aminopeptidase added in step S4 is 1.00%-1.05% w / w, 1.05%-1.10% w / w, 1.10%-1.15% w / w, 1.15%-1.20% w / w, 1.20%-1.25% w / w, 1.25%-1.30% w / w, 1.30%-1.35% w / w, 1.35%-1.40% w / w, 1.40%-1.45% w / w, or 1.45%-1.50% w / w, based on the mass of the buffer solution mentioned in step S4.

[0042] More preferably, the amount of aminopeptidase added in step S4 is 1.0% w / w, 1.2% w / w, or 1.5% w / w of the buffer mass in step S4.

[0043] More preferably, the amount of aminopeptidase added in step S4 is 1.2% w / w of the mass of the buffer solution mentioned in step S4.

[0044] Preferably, the amount of cellulase added in step S4 is 1.0% w / w of the mass of the buffer solution in step S4.

[0045] Specifically, the buffer solution mentioned in step S4 is a phosphate buffer solution.

[0046] Specifically, the pH value of the buffer solution described in step S4 is 4.5-6.5.

[0047] Preferably, the pH value of the buffer solution in step S4 is 4.5-5.0, 5.0-5.5, 5.5-6.0, or 6.0-6.5.

[0048] Specifically, the buffer solution described in step S4 is added at a material-to-liquid ratio of 1g:8-10mL.

[0049] Preferably, the buffer solution described in step S4 is added at a material-to-liquid ratio of 1g:8-9mL or 1g:9-10mL.

[0050] More preferably, the buffer solution in step S4 is added at a material-to-liquid ratio of 1g:8mL.

[0051] Specifically, the enzymatic hydrolysis temperature described in step S4 is 40-50℃.

[0052] Preferably, the enzymatic hydrolysis temperature in step S4 is 40-45℃ or 45-50℃.

[0053] More preferably, the enzymatic hydrolysis temperature in step S4 is 45°C.

[0054] Specifically, the enzymatic hydrolysis time in step S4 is 100-140 min.

[0055] Preferably, the enzymatic hydrolysis time in step S4 is 100-110 min, 110-120 min, 120-130 min, or 130-140 min.

[0056] More preferably, the enzymatic hydrolysis time in step S4 is 120 min.

[0057] Specifically, the enzyme inactivation temperature described in step S4 is 80-90℃.

[0058] Preferably, the enzyme inactivation temperature in step S4 is 80-85℃ or 85-90℃.

[0059] More preferably, the enzyme inactivation temperature in step S4 is 85°C.

[0060] Specifically, the enzyme inactivation time described in step S4 is 5-15 minutes.

[0061] Preferably, the enzyme inactivation time in step S4 is 5-10 min or 10-15 min.

[0062] More preferably, the enzyme inactivation time in step S4 is 10 minutes.

[0063] Specifically, the amount of acidic protease added in step S5 is 0.75%-1.00% w / w of the mass of distilled water mentioned in step S5.

[0064] Preferably, the amount of acidic protease added in step S5 is 0.75%-0.80%w / w, 0.80%-0.85%w / w, 0.85%-0.90%w / w, 0.90%-0.95%w / w, or 0.95%-1.00%w / w of the mass of distilled water in step S5.

[0065] More preferably, the amount of acidic protease added in step S5 is 0.75% w / w or 1.00% w / w of the mass of distilled water in step S5.

[0066] More preferably, the amount of acidic protease added in step S5 is 1.00% w / w of the mass of distilled water in step S5.

[0067] Specifically, the distilled water mentioned in step S5 is added at a material-to-liquid ratio of 1g:10-12mL.

[0068] Preferably, the distilled water mentioned in step S5 is added at a material-to-liquid ratio of 1g:10-11mL or 1g:11-12mL.

[0069] More preferably, the distilled water in step S5 is added at a material-to-liquid ratio of 1g:12mL.

[0070] Specifically, adjusting the pH in step S5 means adjusting the pH value to 3.0-4.0.

[0071] Preferably, the pH adjustment in step S5 is to adjust the pH value to 3.0-3.1, 3.1-3.2, 3.2-3.3, 3.3-3.4, 3.4-3.5, 3.5-3.6, 3.6-3.7, 3.7-3.8, 3.8-3.9 or 3.9-4.0.

[0072] More preferably, the pH adjustment in step S5 is to adjust the pH value to 3.5.

[0073] Specifically, the enzymatic hydrolysis temperature described in step S5 is 50-60℃.

[0074] Preferably, the enzymatic hydrolysis temperature in step S5 is 50-55℃ or 55-60℃.

[0075] More preferably, the enzymatic hydrolysis temperature in step S5 is 55°C.

[0076] Specifically, the enzymatic hydrolysis time in step S5 is 120-180 min.

[0077] Preferably, the enzymatic hydrolysis time in step S5 is 120-130 min, 130-140 min, 140-150 min, 150-160 min, 160-170 min, or 170-180 min.

[0078] More preferably, the enzymatic hydrolysis time in step S5 is 150 min.

[0079] Specifically, the enzyme inactivation temperature described in step S5 is 85-95℃.

[0080] Preferably, the enzyme inactivation temperature in step S5 is 85-90℃ or 90-100℃.

[0081] More preferably, the enzyme inactivation temperature in step S5 is 90°C.

[0082] Specifically, the enzyme inactivation time described in step S5 is 5-15 minutes.

[0083] Preferably, the enzyme inactivation time in step S5 is 5-10 min or 10-15 min.

[0084] More preferably, the enzyme inactivation time in step S5 is 10 minutes.

[0085] Specifically, the concentration described in step S7 is to concentrate to a relative density of 1.10-1.20 at 60°C.

[0086] Preferably, the concentration in step S7 is to concentrate to a relative density of 1.10-1.11, 1.11-1.12, 1.12-1.13, 1.13-1.14, 1.14-1.15, 1.15-1.16, 1.16-1.17, 1.17-1.18, 1.18-1.19 or 1.19-1.20 at 60°C.

[0087] More preferably, the concentration in step S7 is to concentrate to a relative density of 1.15 at 60°C.

[0088] Specifically, the drying process described in step S7 includes freeze drying, vacuum drying, or spray drying.

[0089] Preferably, the drying process in step S7 is spray drying.

[0090] Specifically, the composition comprises the following raw materials in parts by weight: 1-3 parts of Buzha leaf, 1-3 parts of hawthorn, 1-3 parts of lotus leaf, 5-10 parts of wild kudzu root, 10-20 parts of Imperata root and 1-3 parts of litchi seed.

[0091] Preferably, the composition comprises 1-2 parts or 2-3 parts of cloth residue leaves by weight.

[0092] More preferably, the composition comprises 1 part, 2 parts or 3 parts by weight of cloth residue leaves.

[0093] More preferably, the composition comprises 2 parts by weight of cloth leaves.

[0094] Preferably, the composition comprises 1-2 parts or 2-3 parts of hawthorn by weight.

[0095] More preferably, the composition comprises 1 part, 2 parts or 3 parts of hawthorn by weight.

[0096] More preferably, the composition comprises 2 parts by weight of hawthorn.

[0097] Preferably, the composition comprises 1-2 parts or 2-3 parts of lotus leaves by weight.

[0098] More preferably, the composition comprises 1 part, 2 parts or 3 parts of lotus leaf by weight.

[0099] More preferably, the composition comprises 2 parts by weight of lotus leaves.

[0100] Preferably, the composition comprises 5-6 parts, 6-7 parts, 7-8 parts, 8-9 parts, or 9-10 parts of Pueraria lobata by weight.

[0101] More preferably, the composition comprises 5, 8, or 10 parts by weight of Pueraria lobata.

[0102] More preferably, the composition comprises 5 parts by weight of Pueraria lobata.

[0103] Preferably, the composition comprises 10-11 parts, 11-12 parts, 12-13 parts, 13-14 parts, 14-15 parts, 15-16 parts, 16-17 parts, 17-18 parts, 18-19 parts, or 19-20 parts of Imperata cylindrica root by weight.

[0104] More preferably, the composition comprises 10, 15, or 20 parts by weight of Imperata cylindrica root.

[0105] More preferably, the composition comprises 10 parts by weight of Imperata cylindrica root.

[0106] On the other hand, the present invention provides a method for preparing any of the above compositions.

[0107] In another aspect, the present invention provides the use of any of the above-described compositions in the preparation of products, said products comprising any one or more of the following:

[0108] (1) Health supplements that help control body fat;

[0109] (2) Medications that reduce body fat or uric acid.

[0110] In another aspect, the present invention provides a health product, characterized in that the health product comprises the composition described in any one of the above claims.

[0111] Specifically, the dosage forms of the health products include solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

[0112] Preferably, the dosage form of the health product includes, but is not limited to: tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids, or drops.

[0113] Specifically, the health products also include nutritionally acceptable nutritional additives.

[0114] Preferably, the nutritional additives include, but are not limited to, one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0115] In another aspect, the present invention provides a medicine comprising the composition described in any of the preceding claims.

[0116] Preferably, the dosage form of the medicine includes any one or more of the following: tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

[0117] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0118] Preferably, the pharmaceutically acceptable excipients include one or more of the following: wetting agents, emulsifiers, preservatives, antioxidants, buffers, diluents, lubricants, solutes, suspending agents, solubilizers, thickeners, stabilizers, sweeteners, and flavorings.

[0119] In another aspect, the present invention provides a method for helping to control body fat, the method comprising using any of the compositions, health products or pharmaceuticals described above.

[0120] Specifically, the method includes administering an effective amount of the composition, health product, or medicine to the subject.

[0121] Preferably, the subject is a mammal.

[0122] More preferably, the subject is a human being.

[0123] In another aspect, the present invention provides a method for reducing body fat or uric acid, the method comprising using any of the compositions, health products or pharmaceuticals described above.

[0124] Specifically, the method includes administering an effective amount of the composition, health product, or medicine to the subject.

[0125] Preferably, the subject is a mammal.

[0126] More preferably, the subject is a human being.

[0127] The beneficial effects of this invention are as follows:

[0128] The compositions of this invention can be used to prepare health products that help control body fat and pharmaceuticals that reduce body fat or uric acid. Compared with existing products, the compositions of this invention have an advanced preparation process, which can effectively improve the dissolution rate of active ingredients, have a clear mechanism of action, and use natural raw materials with high safety. They have significant effects on fat reduction and uric acid reduction, and possess important application value and broad market prospects. Attached Figure Description

[0129] Figure 1 The results show the uric acid content measurement; the *** in the figure represents the result compared to the control group. P <0.001; **** represents the difference compared to the blank group. P <0.0001; #### represents compared with the model group P <0.0001; $ represents the difference compared to the positive control group. P <0.05; $$ represents the difference compared to the positive control group. P <0.01; $$$$ represents the difference compared to the positive control group. P <0.0001; &&& represents a value compared to Example 1 group. P <0.001; &&&& represents a comparison with Example 1 group P <0.0001.

[0130] Figure 2 The figures show the results of blood triglyceride and total cholesterol measurements; * indicates a comparison with the blank control group. P <0.05; ** indicates a difference compared to the blank control group. P <0.01; **** represents the difference compared to the blank control group. P <0.0001; #### represents the difference compared to the model control group. P <0.0001. Detailed Implementation

[0131] The present invention will be further clearly and completely illustrated below through embodiments. These embodiments are only some examples of the present invention and are not intended to limit the present invention, but are only for illustrating the present invention. Unless otherwise specified, the experimental methods used in the following embodiments are all conventional experiments, and the materials and reagents used in the following embodiments are commercially available unless otherwise specified.

[0132] Example 1

[0133] A composition comprising the following raw materials: 2 parts of *Pueraria lobata* leaves, 2 parts of *Crataegus pinnatifida*, 2 parts of lotus leaves, 5 parts of *Pueraria lobata* root, 10 parts of *Imperata cylindrica* root, and 2 parts of litchi seeds. The preparation method of the composition is as follows:

[0134] 1. Raw material preparation:

[0135] (1) After crushing the leaves of the cloth and lotus leaves through a 40-mesh sieve, they are mixed according to the weight parts to obtain medicinal powder 1;

[0136] (2) Remove the pits from the hawthorn and crush it through a 50-mesh sieve. Crush the lychee seeds into granules and mix them according to the weight to obtain 2 medicinal powders.

[0137] (3) Slice the wild kudzu root and the white grass root and set aside.

[0138] 2. Preparation of the composition:

[0139] S1. Mix the sliced ​​wild kudzu root and the sliced ​​white yam root according to the weight ratio of 1g:10mL, add distilled water, stir evenly, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0140] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase at 1.2% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0141] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0142] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0143] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0144] Example 2

[0145] A composition comprising the following raw materials: 3 parts of *Pueraria lobata* leaves, 1 part of *Crataegus pinnatifida*, 1 part of lotus leaf, 8 parts of *Pueraria lobata* root, 15 parts of *Imperata cylindrica* root, and 1 part of litchi seed. The preparation method of the composition is as follows:

[0146] 1. Raw material preparation: Refer to Example 1.

[0147] 2. Preparation of the composition:

[0148] S1. Mix the sliced ​​Pueraria lobata and Imperata cylindrica according to the weight ratio, add distilled water at a material-to-liquid ratio of 1g:15mL, stir well, add 1.0% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0149] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:10mL, add aminopeptidase at 1.5% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0150] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:15mL, adjust the pH to 3.5, add 0.75% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0151] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0152] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0153] Example 3

[0154] A composition comprising 1 part *Pueraria lobata* leaf, 3 parts *Crataegus pinnatifida*, 3 parts *Nelumbo nucifera* leaf, 10 parts *Pueraria lobata* root, 20 parts *Imperata cylindrica* root, and 3 parts *Lychee spp.* seed. The preparation method of the composition is as follows:

[0155] 1. Raw material preparation: Refer to Example 1.

[0156] 2. Preparation of the composition:

[0157] S1. Mix the sliced ​​Pueraria lobata and Imperata cylindrica according to the weight ratio, add distilled water at a material-to-liquid ratio of 1g:10mL, stir well, add 0.75% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0158] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0159] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:10mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0160] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0161] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0162] Comparative Example 1

[0163] A composition comprising the following raw materials: 2 parts of *Broussonetia papyrifera* leaves, 2 parts of *Crataegus pinnatifida*, 2 parts of lotus leaves, 15 parts of *Imperata cylindrica* root, and 2 parts of litchi seeds. The preparation method of the composition is as follows:

[0164] 1. Raw material preparation:

[0165] (1) After crushing the leaves of the cloth and lotus leaves through a 40-mesh sieve, they are mixed according to the weight parts to obtain medicinal powder 1;

[0166] (2) Remove the pits from the hawthorn and crush it through a 50-mesh sieve. Crush the lychee seeds into granules and mix them according to the weight to obtain 2 medicinal powders.

[0167] (3) Slice the Imperata cylindrica root and set aside.

[0168] 2. Preparation of the composition:

[0169] S1. Slice the Imperata cylindrica root, add distilled water at a material-to-liquid ratio of 1g:10mL, stir well, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0170] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase at 1.2% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0171] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0172] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0173] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0174] Comparative Example 2

[0175] A composition comprising the following raw materials: 4 parts of *Pueraria lobata* leaves, 4 parts of *Crataegus pinnatifida*, 5 parts of *Pueraria lobata* root, and 10 parts of *Imperata cylindrica* root. The preparation method of the composition is as follows:

[0176] 1. Raw material preparation:

[0177] (1) After crushing the leaves of the Buzha leaf through a 40-mesh sieve, the medicinal powder 1 is obtained;

[0178] (2) Remove the pits from the hawthorn, crush it and pass it through a 50-mesh sieve to obtain 2 medicinal powders.

[0179] (3) Slice the wild kudzu root and the white grass root and set aside.

[0180] 2. Preparation of the composition:

[0181] S1. Mix the sliced ​​wild kudzu root and the sliced ​​white yam root according to the weight ratio of 1g:10mL, add distilled water, stir evenly, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0182] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase at 1.2% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0183] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0184] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0185] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0186] Comparative Example 3

[0187] A composition comprising the following raw materials: 4 parts of *Imperata cylindrica* leaves, 4 parts of *Crataegus pinnatifida*, and 15 parts of *Imperata cylindrica* root. The preparation method of the composition is as follows:

[0188] 1. Raw material preparation:

[0189] (1) After crushing the leaves of the Buzha leaf through a 40-mesh sieve, the medicinal powder 1 is obtained;

[0190] (2) Remove the pits from the hawthorn, crush it and pass it through a 50-mesh sieve to obtain 2 medicinal powders.

[0191] (3) Slice the Imperata cylindrica root and set aside.

[0192] 2. Preparation of the composition:

[0193] S1. Slice the Imperata cylindrica root, add distilled water at a material-to-liquid ratio of 1g:10mL, stir well, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0194] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase at 1.2% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0195] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0196] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0197] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0198] Comparative Example 4

[0199] A composition comprising the following raw materials: 2 parts Panax notoginseng leaves, 2 parts Crataegus pinnatifida, 2 parts Nelumbo nucifera leaves, 5 parts Pueraria lobata root, 10 parts Arctium lappa root, and 2 parts Longan seeds. The preparation method of the composition is as follows:

[0200] 1. Raw material preparation:

[0201] (1) After crushing the leaves of Panax notoginseng and lotus leaves through a 40-mesh sieve, they are mixed according to the weight parts to obtain medicinal powder 1;

[0202] (2) Remove the pits from the hawthorn and crush it through a 50-mesh sieve. Crush the longan seeds into granules and mix them according to the weight to obtain 2 medicinal powders.

[0203] (3) Slice the wild kudzu root and burdock root and set aside.

[0204] 2. Preparation of the composition:

[0205] S1. Mix the sliced ​​wild kudzu root and burdock root according to the weight ratio of 1g:10mL, add distilled water, stir evenly, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0206] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add aminopeptidase at 1.2% w / w and cellulase at 1.0% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0207] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0208] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0209] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0210] Comparative Example 5

[0211] A composition comprising the following raw materials: 2 parts of *Pueraria lobata* leaves, 2 parts of *Crataegus pinnatifida*, 2 parts of lotus leaves, 5 parts of *Pueraria lobata* root, 10 parts of *Imperata cylindrica* root, and 2 parts of litchi seeds. The preparation method of the composition is as follows:

[0212] 1. Raw material preparation: Refer to Example 1.

[0213] 2. Preparation of the composition:

[0214] S1. Mix the sliced ​​Pueraria lobata and Imperata cylindrica according to the weight ratio, add distilled water at a material-to-liquid ratio of 1g:10mL, stir well, add 0.5% w / w rhamnolipin by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0215] S2. Combine the medicinal powder 1 and the dregs 1, add phosphate buffer at pH 5.0 according to the material-to-liquid ratio of 1g:8mL, add cellulase at 2.2% w / w of phosphate buffer, enzymatically hydrolyze at 45℃ for 120min, inactivate the enzyme at 85℃ for 10min, and filter to obtain enzymatic hydrolysate 1 and dregs 2.

[0216] S3. Combine the medicinal powder 2 and the dregs 2, add distilled water at a material-to-liquid ratio of 1g:12mL, adjust the pH to 3.5, add 1.0% w / w of acidic protease by weight of distilled water, enzymatically hydrolyze at 55℃ for 150min, inactivate the enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate 2.

[0217] S4. Mix the drug extract, enzyme hydrolysate 1 and enzyme hydrolysate 2 to obtain the enzyme hydrolysate;

[0218] S5. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0219] Comparative Example 6

[0220] A composition comprising the following raw materials: 2 parts of *Pueraria lobata* leaves, 2 parts of *Crataegus pinnatifida*, 2 parts of lotus leaves, 5 parts of *Pueraria lobata* root, 10 parts of *Imperata cylindrica* root, and 2 parts of litchi seeds. The preparation method of the composition is as follows:

[0221] 1. Raw material preparation: Refer to Example 1.

[0222] 2. Preparation of the composition:

[0223] S1. Mix the sliced ​​wild kudzu root and the sliced ​​white yam root according to the weight ratio of 1g:10mL, add distilled water, stir evenly, add 0.5% w / w sophoryl ester by weight of distilled water, soak for 60min, extract at 50℃ for 40min, repeat the extraction and filtration 3 times, combine the filtrates to obtain the drug extract and drug residue 1.

[0224] S2. Combine medicinal powder 1, medicinal powder 2 and dregs 1, add phosphate buffer (pH 5.0) at a material-to-liquid ratio of 1g:12mL, add aminopeptidase, cellulase and acidic protease at a mass of 1.2% w / w in phosphate buffer, enzymatically hydrolyze at 55℃ for 270min, inactivate enzyme at 90℃ for 10min, and filter to obtain enzymatic hydrolysate;

[0225] S3. Mix the drug extract and the enzymatic hydrolysate to obtain the enzymatic hydrolysate;

[0226] S4. Filter the enzymatic extract, concentrate the filtrate to a relative density of 1.15 (60℃), and spray dry to obtain the composition.

[0227] Experimental Example 1: Uric Acid-Lowering Effect of the Composition

[0228] HK-2 cells in logarithmic growth phase were cultured at 2 × 10⁻⁶ cells per well. 5 Cells were seeded in 6-well plates, added with complete culture medium, and cultured for 24 hours. After cell attachment, the culture medium was aspirated, and the cells were washed three times with PBS. The following groups were then administered drugs:

[0229] Blank group: Cultured in complete culture medium for 24 h, the culture medium was aspirated and washed 3 times with PBS, and then cultured in serum-free culture medium for another 24 h;

[0230] Model group: After culturing in complete culture medium for 24 h, the culture medium was aspirated and washed 3 times with PBS, and then cultured in serum-free culture medium containing 0.5 mmol / L adenosine for 24 h.

[0231] Positive control group: cultured in complete medium containing 0.1 mmol / L febuxostat for 24 h, aspirated the culture medium and washed 3 times with PBS, then cultured in serum-free medium containing 0.5 mmol / L adenosine for 24 h.

[0232] Example 1 group: The culture medium containing 500 μg / mL of the composition of Example 1 was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0233] Example 2 group: The culture medium containing 500 μg / mL of the composition of Example 2 was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0234] Example 3 group: The culture medium containing 500 μg / mL of the composition of Example 3 was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0235] Comparative Example 1: The culture medium containing 500 μg / mL of the Comparative Example 1 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0236] Comparative Example 2: The culture medium containing 500 μg / mL of the Comparative Example 2 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0237] Comparative Example 3: The culture medium containing 500 μg / mL of the Comparative Example 3 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0238] Comparative Example 4: The culture medium containing 500 μg / mL of the Comparative Example 4 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0239] Comparative Example 5: The culture medium containing 500 μg / mL of the Comparative Example 5 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0240] Comparative Example 6: The culture medium containing 500 μg / mL of the Comparative Example 6 composition was cultured for 24 h. The culture medium was aspirated and washed 3 times with PBS. Then, the culture medium was replaced with serum-free medium containing 0.5 mmol / L adenosine and cultured for 24 h.

[0241] After the above grouping and treatment were completed, each group was incubated with 0.005 U / mL xanthine oxidase for 1 h, and the cell supernatant was collected. The uric acid content was then determined according to the kit instructions. If the uric acid content in the cell supernatant of the model group was significantly higher than that of the blank control group (…), the uric acid level was considered significantly higher. P <0.0001), the final uric acid production in the positive control group was significantly lower than that in the model group ( P The results showed a concentration-dose effect (<0.0001), indicating that the model was basically successfully constructed. The measurement results are shown in Table 1 and... Figure 1 As shown.

[0242] Table 1

[0243]

[0244] Uric acid test results showed that the compositions of Examples 1-3 and Comparative Examples 1-6 significantly reduced uric acid levels in the model groups. Examples 1-3 showed better uric acid-lowering effects than the positive control group, with Example 1 showing the best uric acid reduction effect. P <0.0001).

[0245] Experimental Example 2: Fat-reducing effect of the composition

[0246] Thirty 5-week-old male C57BL / 6J mice were randomly divided into a blank control group and an experimental group after 7 days of acclimatization. Mice in the blank control group were fed a maintenance diet daily, while mice in the experimental group were fed a high-fat diet daily. After 12 weeks, the average weight of mice in the blank control group was taken, and the weight of mice in the experimental group was also taken. If the weight of mice in the experimental group was ≥ 120% of the average weight of mice in the blank control group, the model was considered successfully established. The experimental group mice were then randomly divided into a model group and Example 1-Example 3 groups, with 6 mice in each group. Different intervention methods were applied to the mice in different groups after grouping.

[0247] Blank control group: continued to be fed a mouse maintenance diet; Model control group: continued to be fed a high-fat diet; Example 1-Example 3 groups: continued to be fed a high-fat diet, and were simultaneously administered 500 mg / kg of the combination of Example 1-Example 3 by gavage daily. After 6 weeks of intervention, the body weight, blood triglyceride (TG), and total cholesterol (TC) levels of mice in each group were measured. The results are shown in Table 2 and... Figure 2 As shown.

[0248] Table 2

[0249]

[0250] The test results showed that the compositions of Examples 1-3 of the present invention could significantly reduce the levels of TG and TC in the blood of mice in the model control group. P <0.0001). The compositions of Examples 1-3 were able to restore the TG content to normal levels, with no significant difference compared to the blank control group; the composition of Example 1 was able to restore the TC content to normal levels, with no significant difference compared to the blank control group.

[0251] The above detailed description is a specific illustration of one feasible embodiment of the present invention, and this embodiment is not intended to limit the patent scope of the present invention. It should be noted that all equivalent implementations or modifications made without departing from the present invention should be included within the scope of the technical solution of the present invention. Therefore, the protection scope of the present invention should be determined by the appended claims.

Claims

1. A composition for reducing fat and uric acid, characterized by, The composition is composed of the following raw materials: Imperata cylindra, Radix Puerariae Thomsonae, Folium Nelumbinis, Radix Puerariae Thomsonae, Imperata cylindra and Litchi chinensis Sonn. The preparation method of the composition is as follows: S1, crushing and sieving the Imperata cylindra and Folium Nelumbinis to obtain medicinal powder 1; S2, crushing and sieving the Radix Puerariae Thomsonae and crushing the Litchi chinensis Sonn to obtain medicinal powder 2; S3, mixing the Radix Puerariae Thomsonae and Imperata cylindra, adding distilled water, stirring uniformly, adding sophorolipid, soaking, repeating extraction and filtration 3 times, combining the filtrates to obtain medicinal extraction liquid and dregs 1; S4, combining the medicinal powder 1 and dregs 1, adding buffer solution, adding aminopeptidase and cellulase, enzymolysis, enzyme inactivation, filtration to obtain enzymolysis liquid 1 and dregs 2; S5, combining the medicinal powder 2 and dregs 2, adding distilled water, adjusting pH, adding acid protease, enzymolysis, enzyme inactivation, filtration to obtain enzymolysis liquid 2; S6, mixing the medicinal extraction liquid, enzymolysis liquid 1 and enzymolysis liquid 2 to obtain enzymolysis extraction liquid; S7, filtering the enzymolysis extraction liquid, concentrating and drying to obtain the composition. The composition is composed of the following raw materials by weight:

2. The composition of claim 1, wherein, 1-3 parts of Imperata cylindra, 1-3 parts of Radix Puerariae Thomsonae, 1-3 parts of Folium Nelumbinis, 5-10 parts of Radix Puerariae Thomsonae, 10-20 parts of Imperata cylindra and 1-3 parts of Litchi chinensis Sonn.

3. The composition of claim 1, wherein, The addition amount of the sophorolipid in step S3 is 0.5%-1.0% w / w of the mass of the distilled water in step S3; the addition amount of the aminopeptidase in step S4 is 1.0%-1.5% w / w of the mass of the buffer solution in step S4; the addition amount of the cellulase in step S4 is 1.0% w / w of the mass of the buffer solution in step S4; the addition amount of the acid protease in step S5 is 0.75%-1.0% w / w of the mass of the distilled water in step S5.

4. The composition of claim 1, wherein, The addition amount of the sophorolipid in step S3 is 1.0% w / w of the mass of the distilled water in step S3; the addition amount of the aminopeptidase in step S4 is 1.0%-1.2% w / w of the mass of the buffer solution in step S4; the addition amount of the cellulase in step S4 is 1.0% w / w of the mass of the buffer solution in step S4; the addition amount of the acid protease in step S5 is 1.0% w / w of the mass of the distilled water in step S5. The distilled water in step S3 is added according to the solid-liquid ratio of 1g:10-15mL; The buffer solution in step S4 is added according to the solid-liquid ratio of 1g:8-10mL; 5. The composition of claim 1, wherein The distilled water in step S5 is added according to the solid-liquid ratio of 1g:10-12mL. The composition is composed of the following raw materials by weight: 2 parts of Imperata cylindra, 2 parts of Radix Puerariae Thomsonae, 2 parts of Folium Nelumbinis, 5 parts of Radix Puerariae Thomsonae, 10 parts of Imperata cylindra and 2 parts of Litchi chinensis Sonn.

7. Use of a composition according to any one of claims 1 to 5 for the manufacture of a product, characterized in that, 6. The preparation method of the composition of any one of claims 1-5. The product includes any one or more of the following: (1) health care products for helping to control body fat; 8. A health product, characterized by, (2) drugs for reducing body fat or reducing uric acid. The health care product is prepared from the composition of any one of claims 1-5.

9. A medicine, characterized in that, The pharmaceutical product is prepared from the composition according to any one of claims 1 to 5. The pharmaceutical product is prepared from the composition according to any one of claims 1 to 5.

Images